Passive stent coatings in the drug-eluting era.
Advances in coronary stent technology, both in terms of stent design and function, have significantly improved the safety and efficacy of percutaneous coronary intervention, including marked reduction in restenosis. This has led to its use in increasingly challenging clinical and lesional subsets, with potential for increased risk of stent-associated thrombosis. In this article we outline the development of passive stent coatings, and evaluate the ongoing role of such coatings in the contemporary era of antiproliferative drug-eluting stents.
Menown
Ian
I
Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Canada. ian@imenown.freeserve.co.uk
Lowe
Rob
R
Penn
Ian
I
D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000517:prevention & control*; D016503:Drug Delivery Systems; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D012449:Safety; D015607:Stents / Q000639:trends*; D013927:Thrombosis / Q000139:chemically induced
D020099:Coated Materials, Biocompatible; D005343:Fibrinolytic Agents; D006493:Heparin